Ascletis (1672.HK) +7.03% pre-market Jan 2026: FDA IND clearance signals upside
1672.HK stock jumps pre-market; FDA IND for ASC30 cited. Meyka AI forecast sees 12-month target HK$25.02.
Track the most active Hong Kong stocks and market trends powered by MEYKA AI.
1672.HK stock jumps pre-market; FDA IND for ASC30 cited. Meyka AI forecast sees 12-month target HK$25.02.
Pre-market: 1746.HK stock falls 10.53% to HK$0.255 on 07 Jan 2026; oversold signals and Meyka AI forecast noted
Pre-market 07 Jan 2026 update on 0202.HK stock: HK$0.136, +7.09%, volume 540,000. Meyka AI analysis and forecast
2152.HK stock sees a pre-market volume spike on HKSE 07 Jan 2026; quick technical and forecast check
Market close: 8121.HK stock fell to HK$0.76 (-10.59%) on 06 Jan 2026. Quick fundamentals, Meyka forecast and price targets.
8172.HK stock fell to HK$0.19 on 06 Jan 2026; our Meyka AI forecast shows a 15.78% 12-month upside to HK$0.22
3988.HK stock at HK$4.46: key metrics, Meyka grade and 12‑month forecast to HK$5.56 (HKSE, Hong Kong)
0489.HK stock closes HK$5.97 on 06 Jan 2026 with volume 241,126,605; Meyka analysis and 12-month forecast.
0682.HK stock rises 8.77% to HKD 0.31 on 06 Jan 2026. Quick analysis, Meyka grade and a 0.35 HKD forecast with 12.90% implied upside
8109.HK stock closed HK$0.034 on 06 Jan 2026 with 257,076,750 shares traded. Quick fundamentals, Meyka grade and forecast included.